Translational Oncology at the University Medical Center of the Johannes-Gutenberg University Mainz (TRON gGmbH), Freiligrathstraße 12, Mainz 55131, Germany; BioNTech AG, An der Goldgrube 12, 55131 Mainz, Germany.
BioNTech AG, An der Goldgrube 12, 55131 Mainz, Germany.
J Immunol Methods. 2018 Jul;458:74-82. doi: 10.1016/j.jim.2018.04.007. Epub 2018 Apr 21.
Cell-based assays to monitor antigen-specific T-cell responses are characterized by their high complexity and should be conducted under controlled conditions to lower multiple possible sources of assay variation. However, the lack of standard reagents makes it difficult to directly compare results generated in one lab over time and across institutions. Therefore TCR-engineered reference samples (TERS) that contain a defined number of antigen-specific T cells and continuously deliver stable results are urgently needed. We successfully established a simple and robust TERS technology that constitutes a useful tool to overcome this issue for commonly used T-cell immuno-assays. To enable users to generate large-scale TERS, on-site using the most commonly used electroporation (EP) devices, an RNA-based kit approach, providing stable TCR mRNA and an optimized manufacturing protocol were established. In preparation for the release of this immuno-control kit, we established optimal EP conditions on six devices and initiated an extended RNA stability study. Furthermore, we coordinated on-site production of TERS with 4 participants. Finally, a proficiency panel was organized to test the unsupervised production of TERS at different laboratories using the kit approach. The results obtained show the feasibility and robustness of the kit approach for versatile in-house production of cellular control samples.
基于细胞的检测方法用于监测抗原特异性 T 细胞反应,其特点是具有高度复杂性,应在受控条件下进行,以降低检测中多种可能的来源的变化。然而,缺乏标准试剂使得难以在不同时间和不同机构之间直接比较在一个实验室中生成的结果。因此,急需具有明确数量的抗原特异性 T 细胞并持续提供稳定结果的 TCR 工程参考样本(TERS)。我们成功地建立了一种简单而强大的 TERS 技术,该技术为常用的 T 细胞免疫检测提供了一种有用的工具来克服这个问题。为了使用户能够使用最常用的电穿孔(EP)设备在现场生成大规模的 TERS,建立了基于 RNA 的试剂盒方法,提供稳定的 TCR mRNA 和优化的制造方案。在发布这种免疫控制试剂盒之前,我们在六台设备上建立了最佳的 EP 条件,并开始了一项扩展的 RNA 稳定性研究。此外,我们协调了 4 名参与者的现场生产。最后,组织了一个熟练小组,使用试剂盒方法在不同实验室测试 TERS 的无监督生产。所得结果表明,该试剂盒方法适用于各种细胞控制样本的灵活内部生产,具有可行性和稳健性。